Results 151 to 160 of about 11,153 (206)

Long-term primary pharmacotherapy of giant prolactinomas: A comparison of different cabergoline dosages. [PDF]

J Clin Transl Endocrinol
Václav H, Manuela V, Michal K, Adéla K, Jana J, Mikuláš K, Pavel D, David N, Václav M, Martin M, Roman L, Václav H.   +11 more
europepmc   +1 more source

Transcutaneous auricular vagus nerve stimulation for paroxysmal sympathetic hyperactivity syndrome after intracerebral hemorrhage: a hypothesis-generating case report. [PDF]

Front Neurosci
Han X, Huang Z, Gao Z, Feng Y, Li Y.
europepmc   +1 more source

Bromocriptine in type 2 diabetes: a promising alternative, a systematic review and meta-analysis. [PDF]

Cardiovasc Diabetol Endocrinol Rep
Dara T, Zabihi M, Hoseinzade F, Rohani M, Saghafi F.   +4 more
europepmc   +1 more source

Treatment of Acromegaly with Bromocriptine

Australian and New Zealand Journal of Medicine, 1979
Summary: Five men and three women with active acromegaly were treated with bromocriptine. After three months' therapy (30 mglday) mean GH during the day decreased by 50% in six out of eight subjects. In the remaining two subjects (non‐responders) GH was persistently over 100 μg/1.
Yeung, RTT, Wang, C, Chan, V
openaire   +5 more sources

Solid Lipid Nanoparticles as Delivery Systems for Bromocriptine

Pharmaceutical Research, 2008
Purpose. The present investigation describes a formulative study for the development of innovative drug delivery systems for bromocriptine. Methods.
Elisabetta Esposito, Matteo Marti, Markus Drechsler   +2 more
exaly   +2 more sources

Postpartum Cerebral Angiopathy Possibly Due to Bromocriptine Therapy

Stroke, 1995
Background Eight cases of benign angiopathy of the postpartum period have been reported previously, none of which involved the administration of bromocriptine.
M Hommel, F Mounier-Vehier, X Leclerc
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Immunomodulation by bromocriptine

Immunopharmacology, 1983
Treatment of rats with the dopaminergic ergot alkaloid bromocriptine (BRC) inhibited the following immune reactions: contact sensitivity skin reaction to dinitrochlorobenzene (DNCB); antibody formation to sheep red blood cells and to bacterial lipopolysaccharide; adjuvant arthritis; and experimental allergic encephalitis. Immunosuppressive doses of BRC
E, Nagy, I, Berczi, G E, Wren, S L, Asa, K, Kovacs   +4 more
openaire   +2 more sources

Bromocriptine and Hallucinations

Annals of Internal Medicine, 1984
Excerpt To the editor: Vance and associates (1) state in their review on bromocriptine, "Hallucinations have been associated with bromocriptine treatment in patients with Parkinson's disease but ar...
openaire   +2 more sources

Bromocriptine

Medicinal Research Reviews, 1987
H, Roehrich, C A, Dackis, M S, Gold
openaire   +2 more sources

BROMOCRIPTINE IN GLAUCOMA

The Lancet, 1984
Q A, Mekki, P, Turner
openaire   +2 more sources